Positive New Data Presented at the Annual Meeting of the American Urological Association Demonstrates Clinical Use for Nanosphere, Inc.'s Ultra-Sensitive PSA Assay

NORTHBROOK, Ill., May 18, 2011 (GLOBE NEWSWIRE) -- Positive clinical studies using Nanosphere Inc.'s (Nasdaq:NSPH) Verisens™ ultra-sensitive PSA assay (research use only) were presented in moderated poster sessions at the annual meeting of the American Urological Association (AUA). The test differentiated men with recurrent cancer (median PSA = 22.2 pg/ml) from men with no recurrence (median PSA = 3.2 pg/ml) in a study of 367 men.